BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $21.6667.

A number of research analysts have issued reports on BCRX shares. Needham & Company LLC cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Cantor Fitzgerald increased their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Larson Financial Group LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth bought a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares in the last quarter. Hilltop Holdings Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $98,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $81,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 3.5%

BCRX stock opened at $9.65 on Thursday. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $10.94. The company has a market cap of $2.45 billion, a P/E ratio of -5.42 and a beta of 0.55. The business has a fifty day moving average of $8.92 and a 200-day moving average of $8.30.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.20 EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals will post -2.66 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.